Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Molecular tracing of prostate cancer lethality

Oncogene volume 39, pages 7225–7238 (2020)Cite this article

Subjects

Abstract

Prostate cancer is diagnosed mostly in men over the age of 50 years, and has favorable 5-year survival rates due to early cancer detection and availability of curative surgical management. However, progression to metastasis and emergence of therapeutic resistance are responsible for the majority of prostate cancer mortalities. Recent advancement in sequencing technologies and computational capabilities have improved the ability to organize and analyze large data, thus enabling the identification of novel biomarkers for survival, metastatic progression and patient prognosis. Large-scale sequencing studies have also uncovered genetic and epigenetic signatures associated with prostate cancer molecular subtypes, supporting the development of personalized targeted-therapies. However, the current state of mainstream prostate cancer management does not take full advantage of the personalized diagnostic and treatment modalities available. This review focuses on interrogating biomarkers of prostate cancer progression, including gene signatures that correspond to the acquisition of tumor lethality and those of predictive and prognostic value in progression to advanced disease, and suggest how we can use our knowledge of biomarkers and molecular subtypes to improve patient treatment and survival outcomes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Molecular contributors to prostate cancer aggressiveness.
Fig. 2: Tracing prostate cancer trajectory using a molecular atlas-based personalized strategy.

Similar content being viewed by others

References

  1. Oon SF, Pennington SR, Fitzpatrick JM, Watson RW. Biomarker research in prostate cancer–towards utility, not futility. Nat Rev Urol. 2011;3:131–8.

    Google Scholar 

  2. Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: an important clinical entity. Nat Rev Urol. 2014;6:317–23.

    Google Scholar 

  3. Howlader NNA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, et al. (eds). SEER Cancer Statistics Review (CSR), 1975-2016. National Cancer Institute, Bethesda, MD [online]. 2019.

  4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;1:7–30.

    Google Scholar 

  5. Merrill RM, Lyon JL. Explaining the difference in prostate cancer mortality rates between white and black men in the United States. Urology. 2000;5:730–5.

    Google Scholar 

  6. Sun YF, Yang XR, Zhou J, Qiu SJ, Fan J, Xu Y. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol. 2011;8:1151–73.

    Google Scholar 

  7. Kalin M, Cima I, Schiess R, Fankhauser N, Powles T, Wild P, et al. Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome. Eur Urol. 2011;6:1235–43.

    Google Scholar 

  8. Osorio LA, Farfan NM, Castellon EA, Contreras HR. SNAIL transcription factor increases the motility and invasive capacity of prostate cancer cells. Mol Med Rep. 2016;1:778–86.

    Google Scholar 

  9. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011;7333:269–73.

    Google Scholar 

  10. Buchheit CL, Weigel KJ, Schafer ZT. Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer. 2014;9:632–41.

    Google Scholar 

  11. Nolan KD, Franco OE, Hance MW, Hayward SW, Isaacs JS. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion. J Biol Chem. 2015;13:8271–82.

    Google Scholar 

  12. Broustas CG, Zhu A, Lieberman HB. Rad9 protein contributes to prostate tumor progression by promoting cell migration and anoikis resistance. J Biol Chem. 2012;49:41324–33.

    Google Scholar 

  13. Gajula RP, Chettiar ST, Williams RD, Thiyagarajan S, Kato Y, Aziz K, et al. The twist box domain is required for Twist1-induced prostate cancer metastasis. Mol Cancer Res. 2013;11:1387–400.

    CAS  PubMed  Google Scholar 

  14. Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M, et al. Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. Mol Cancer Res. 2013;4:405–17.

    Google Scholar 

  15. Zhang K, Myllymäki SM, Gao P, Devarajan R, Kytölä V, Nykter M, et al. Oncogenic K-Ras upregulates ITGA6 expression via FOSL1 to induce anoikis resistance and synergizes with αV-Class integrins to promote EMT. Oncogene 2017;41:5681–5694.

    Google Scholar 

  16. Kwon OJ, Valdez JM, Zhang L, Zhang B, Wei X, Su Q, et al. Increased Notch signalling inhibits anoikis and stimulates proliferation of prostate luminal epithelial cells. Nat Commun. 2014;5:4416–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Lee JW, Kim JH. Activation of the leukotriene B4 receptor 2-reactive oxygen species (BLT2-ROS) cascade following detachment confers anoikis resistance in prostate cancer cells. J Biol Chem. 2013;42:30054–63.

    Google Scholar 

  18. Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nat Commun. 2011;2:162–70.

    PubMed  PubMed Central  Google Scholar 

  19. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;2:69–84.

    Google Scholar 

  20. Clarke NW, Hart CA, Brown MD. Molecular mechanisms of metastasis in prostate cancer. Asian J Androl. 2009;1:57–67.

    Google Scholar 

  21. Wang X, Dong B, Zhang K, Ji Z, Cheng C, Zhao H, et al. E-cadherin bridges cell polarity and spindle orientation to ensure prostate epithelial integrity and prevent carcinogenesis in vivo. PLoS Genet. 2018;8:e1007609.

    Google Scholar 

  22. Olson A, Le V, Aldahl J, Yu EJ, Hooker E, He Y, et al. The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression. PLoS Genet. 2019;10:e1008451.

    Google Scholar 

  23. Bougen NM, Amiry N, Yuan Y, Kong XJ, Pandey V, Vidal LJ, et al. Trefoil factor 1 suppression of E-CADHERIN enhances prostate carcinoma cell invasiveness and metastasis. Cancer Lett. 2013;1:19–29.

    Google Scholar 

  24. Borno ST, Fischer A, Kerick M, Falth M, Laible M, Brase JC, et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Disco. 2012;11:1024–35.

    Google Scholar 

  25. Karanikolas BD, Figueiredo ML, Wu L. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate 2010;6:675–88.

    Google Scholar 

  26. Munkley J, McClurg UL, Livermore KE, Ehrmann I, Knight B, McCullagh P, et al. The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. Sci Rep. 2017;1:5249.

    Google Scholar 

  27. Copeland BT, Bowman MJ, Ashman LK. Genetic ablation of the tetraspanin CD151 reduces spontaneous metastatic spread of prostate cancer in the TRAMP model. Mol Cancer Res. 2013;1:95–105.

    Google Scholar 

  28. Han R, Hensley PJ, Li J, Zhang Y, Stark TW, Heller A, et al. Integrin-associated CD151 is a suppressor of prostate cancer progression. Am J Transl Res. 2020;4:1428–42.

    Google Scholar 

  29. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;6:873–87.

    Google Scholar 

  30. Nilsson EM, Laursen KB, Whitchurch J, McWilliam A, Odum N, Persson JL, et al. MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators. Oncotarget. 2015;34:35710–25.

    Google Scholar 

  31. Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;12:701–11.

    Google Scholar 

  32. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;3:298–305.

    Google Scholar 

  33. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;7406:239–43.

    Google Scholar 

  34. Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer. 2009;6:888–93.

    Google Scholar 

  35. Fisher G, Yang ZH, Kudahetti S, Moller H, Scardino P, Cuzick J, et al. Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort. Br J Cancer. 2013;2:271–7.

    Google Scholar 

  36. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;3:245–55.

    Google Scholar 

  37. Majid S, Dar AA, Saini S, Arora S, Shahryari V, Zaman MS, et al. miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res. 2012;24:6435–46.

    Google Scholar 

  38. Figiel S, Vasseur C, Bruyere F, Rozet F, Maheo K, Fromont G. Clinical significance of epithelial-mesenchymal transition markers in prostate cancer. Hum Pathol. 2017;61:26–32.

    CAS  PubMed  Google Scholar 

  39. Bilir B, Osunkoya AO, Wiles WGT, Sannigrahi S, Lefebvre V, Metzger D, et al. SOX4 is essential for prostate tumorigenesis initiated by PTEN ablation. Cancer Res. 2016;5:1112–21.

    Google Scholar 

  40. Chien MH, Lin YW, Wen YC, Yang YC, Hsiao M, Chang JL, et al. Targeting the SPOCK1-snail/slug axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis. J Exp Clin Cancer Res. 2019;1:246.

    Google Scholar 

  41. Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell. 2010;4:319–32.

    Google Scholar 

  42. Dey P, Velazquez-Villegas LA, Faria M, Turner A, Jonsson P, Webb P, et al. Estrogen receptor β2 induces hypoxia signature of gene expression by stabilizing HIF-1α in prostate cancer. PLoS ONE. 2015;5:e0128239.

    Google Scholar 

  43. Yi C, Wan X, Zhang Y, Fu F, Zhao C, Qin R, et al. SNORA42 enhances prostate cancer cell viability, migration and EMT and is correlated with prostate cancer poor prognosis. Int J Biochem Cell Biol. 2018;102:138–50.

    CAS  PubMed  Google Scholar 

  44. Zheng J, Zhao S, He X, Zheng Z, Bai W, Duan Y, et al. The up-regulation of long non-coding RNA CCAT2 indicates a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2016;4:508–14.

    Google Scholar 

  45. Ramalho-Carvalho J, Martins JB, Cekaite L, Sveen A, Torres-Ferreira J, Graca I, et al. Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. Cancer Lett. 2017;385:150–9.

    CAS  PubMed  Google Scholar 

  46. Xu S, Yi XM, Tang CP, Ge JP, Zhang ZY, Zhou WQ. Long non-coding RNA ATB promotes growth and epithelial-mesenchymal transition and predicts poor prognosis in human prostate carcinoma. Oncol Rep. 2016;1:10–22.

    Google Scholar 

  47. Skvortsova K, Masle-Farquhar E, Luu PL, Song JZ, Qu W, Zotenko E, et al. DNA hypermethylation encroachment at CpG island borders in cancer is predisposed by H3K4 monomethylation patterns. Cancer Cell. 2019;2:297–314. e8.

    Google Scholar 

  48. Williams LV, Veliceasa D, Vinokour E, Volpert OV. miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS ONE. 2013;12:e83991.

    Google Scholar 

  49. Majid S, Dar AA, Saini S, Shahryari V, Arora S, Zaman MS, et al. miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res. 2013;1:73–84.

    Google Scholar 

  50. Guan B, Wu K, Zeng J, Xu S, Mu L, Gao Y, et al. Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer. Oncotarget 2017;5:8162–72.

    Google Scholar 

  51. Ramalinga M, Roy A, Srivastava A, Bhattarai A, Harish V, Suy S, et al. MicroRNA-212 negatively regulates starvation induced autophagy in prostate cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis and cellular senescence. Oncotarget 2015;33:34446–57.

    Google Scholar 

  52. Lin ZY, Chen G, Zhang YQ, He HC, Liang YX, Ye JH, et al. MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer. Mol Cancer. 2017;1:48.

    Google Scholar 

  53. Wang Z, Xu L, Hu Y, Huang Y, Zhang Y, Zheng X, et al. miRNA let-7b modulates macrophage polarization and enhances tumor-associated macrophages to promote angiogenesis and mobility in prostate cancer. Sci Rep. 2016;6:25602–610.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Formosa A, Lena AM, Markert EK, Cortelli S, Miano R, Mauriello A, et al. DNA methylation silences miR-132 in prostate cancer. Oncogene. 2013;1:127–34.

    Google Scholar 

  55. Mostaghel EA, Zhang A, Hernandez S, Marck BT, Zhang X, Tamae D, et al. Contribution of adrenal glands to intratumor androgens and growth of castration-resistant prostate cancer. Clin Cancer Res. 2019;1:426–39.

    Google Scholar 

  56. Bauman DR, Steckelbroeck S, Williams MV, Peehl DM, Penning TM. Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease. Mol Endocrinol. 2006;2:444–58.

    Google Scholar 

  57. Liu C, Yang JC, Armstrong CM, Lou W, Liu L, Qiu X, et al. AKR1C3 promotes AR-V7 protein stabilization and confers resistance to AR-targeted therapies in advanced prostate cancer. Mol Cancer Ther. 2019;10:1875–86.

    Google Scholar 

  58. Yepuru M, Wu Z, Kulkarni A, Yin F, Barrett CM, Kim J, et al. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clin Cancer Res. 2013;20:5613–25.

    Google Scholar 

  59. Liu C, Armstrong CM, Lou W, Lombard A, Evans CP, Gao AC. Inhibition of AKR1C3 activation overcomes resistance to abiraterone in advanced prostate cancer. Mol Cancer Ther. 2017;1:35–44.

    Google Scholar 

  60. Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, et al. Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Res. 2015;7:1413–22.

    Google Scholar 

  61. Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell. 2013;5:1074–84.

    Google Scholar 

  62. Hearn JWD, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, et al. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol. 2016;10:1435–44.

    Google Scholar 

  63. Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res. 2019;23:6916–24.

    Google Scholar 

  64. Reyes EE, VanderWeele DJ, Isikbay M, Duggan R, Campanile A, Stadler WM, et al. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Med. 2014;12:1313–19.

    Google Scholar 

  65. Zhang T, Karsh LI, Nissenblatt MJ, Canfield SE. Androgen receptor splice variant, AR-V7, as a biomarker of resistance to androgen axis-targeted therapies in advanced prostate cancer. Clin Genitourin Cancer. 2020;1:1–10.

    Google Scholar 

  66. Liu C, Armstrong C, Zhu Y, Lou W, Gao AC. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget. 2016;22:32210–20.

    Google Scholar 

  67. Zhao J, Ning S, Lou W, Yang JC, Armstrong CM, Lombard AP, et al. Cross-resistance among next-generation antiandrogen drugs through the AKR1C3/AR-V7 axis in advanced prostate cancer. Mol Cancer Ther. 2020;8:1708–18.

    Google Scholar 

  68. Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia. 2013;1:1–10.

    Google Scholar 

  69. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol. 2011;6:820–8.

    Google Scholar 

  70. Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res. 2014;4:890–903.

    Google Scholar 

  71. Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, et al. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Rep. 2015;6:922–36.

    Google Scholar 

  72. Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell. 2007;6:917–31.

    Google Scholar 

  73. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;5:575–86.

    Google Scholar 

  74. Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, et al. N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell. 2016;4:563–77.

    Google Scholar 

  75. Fraser JA, Sutton JE, Tazayoni S, Bruce I, Poole AV. hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen. Sci Rep. 2019;1:19076.

    Google Scholar 

  76. Marin-Aguilera M, Reig O, Mila-Guasch M, Font A, Domenech M, Rodriguez-Vida A, et al. The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer. Int J Cancer. 2019;7:1970–81.

    Google Scholar 

  77. Yang YJ, Kong YY, Li GX, Wang Y, Ye DW, Dai B. Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer. BJU Int. 2019;2:258–67.

    Google Scholar 

  78. Beltran H, Wyatt AW, Chedgy EC, Donoghue A, Annala M, Warner EW, et al. Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy. Clin Cancer Res. 2017;22:6802–11.

    Google Scholar 

  79. Harris KS, Kerr BA. Prostate cancer stem cell markers drive progression, therapeutic resistance, and bone metastasis. Stem Cells Int. 2017;2017:8629234.

    PubMed  PubMed Central  Google Scholar 

  80. Lassi K, Dawson NA. Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol. 2010;3:263–7.

    Google Scholar 

  81. Labrecque MP, Takhar MK, Nason R, Santacruz S, Tam KJ, Massah S, et al. The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells. Oncotarget. 2016;17:24284–302.

    Google Scholar 

  82. Chen X, Li Q, Liu X, Liu C, Liu R, Rycaj K, et al. Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate cancer. Clin Cancer Res. 2016;17:4505–16.

    Google Scholar 

  83. Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, et al. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol. 2018;2:352–60.

    Google Scholar 

  84. Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015;6254:1351–6.

    Google Scholar 

  85. Cajigas-Du Ross CK, Martinez SR, Woods-Burnham L, Duran AM, Roy S, Basu A, et al. RNA sequencing reveals upregulation of a transcriptomic program associated with stemness in metastatic prostate cancer cells selected for taxane resistance. Oncotarget. 2018;54:30363–84.

    Google Scholar 

  86. Kanwal R, Shukla S, Walker E, Gupta S. Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics. Cancer Lett. 2018;430:25–33.

    CAS  PubMed  Google Scholar 

  87. Reyes EE, Gillard M, Duggan R, Wroblewski K, Kregel S, Isikbay M, et al. Molecular analysis of CD133-positive circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Sci. 2015;1:1–6.

    Google Scholar 

  88. Canovas V, Punal Y, Maggio V, Redondo E, Marin M, Mellado B, et al. Prostate tumor overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells. Oncotarget. 2017;35:59165–80.

    Google Scholar 

  89. Lombard AP, Liu C, Armstrong CM, Cucchiara V, Gu X, Lou W, et al. ABCB1 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer. Mol Cancer Ther. 2017;10:2257–66.

    Google Scholar 

  90. Ramachandran K, Speer C, Nathanson L, Claros M, Singal R. Role of DNA methylation in cabazitaxel resistance in prostate cancer. Anticancer Res. 2016;1:161–8.

    Google Scholar 

  91. Galletti G, Leach BI, Lam L, Tagawa ST. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev. 2017;57:16–27.

    CAS  PubMed  Google Scholar 

  92. Sekino Y, Han X, Kawaguchi T, Babasaki T, Goto K, Inoue S, et al. TUBB3 Reverses resistance to docetaxel and cabazitaxel in prostate cancer. Int J Mol Sci. 2019;20:16–22.

    Google Scholar 

  93. Al Nakouzi N, Le Moulec S, Albiges L, Wang C, Beuzeboc P, Gross-Goupil M, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. 2015;2:228–35.

    Google Scholar 

  94. van Soest RJ, de Morree ES, Kweldam CF, de Ridder CMA, Wiemer EAC, Mathijssen RHJ, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur Urol. 2015;6:981–5.

    Google Scholar 

  95. van Soest RJ, Nieuweboer AJ, de Morree ES, Chitu D, Bergman AM, Goey SH, et al. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2015;17:2562–9.

    Google Scholar 

  96. Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol. 2014;3:459–65.

    Google Scholar 

  97. Mout L, de Wit R, Stuurman D, Verhoef E, Mathijssen R, de Ridder C, et al. Testosterone diminishes cabazitaxel efficacy and intratumoral accumulation in a prostate cancer xenograft model. EBioMedicine. 2018;27:182–6.

    PubMed  Google Scholar 

  98. Conteduca V, Castro E, Wetterskog D, Scarpi E, Jayaram A, Romero-Laorden N, et al. Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. Eur J Cancer. 2019;116:158–68.

    CAS  PubMed  Google Scholar 

  99. Martin SK, Pu H, Penticuff JC, Cao Z, Horbinski C, Kyprianou N. Multinucleation and mesenchymal-to-epithelial transition alleviate resistance to combined cabazitaxel and antiandrogen therapy in advanced prostate cancer. Cancer Res. 2016;4:912–26.

    Google Scholar 

  100. Helpap B, Egevad L. Modified Gleason grading. An updated review. Histol Histopathol. 2009;5:661–6.

    Google Scholar 

  101. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;17:1591–7.

    Google Scholar 

  102. Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011;18:2574–81.

    Google Scholar 

  103. Hudson BD, Kulp KS, Loots GG. Prostate cancer invasion and metastasis: insights from mining genomic data. Brief Funct Genomics. 2013;5:397–410.

    Google Scholar 

  104. Luo Y, Jiang QW, Wu JY, Qiu JG, Zhang WJ, Mei XL, et al. Regulation of migration and invasion by Toll-like receptor-9 signaling network in prostate cancer. Oncotarget. 2015;26:22564–74.

    Google Scholar 

  105. Ok S, Kim SM, Kim C, Nam D, Shim BS, Kim SH, et al. Emodin inhibits invasion and migration of prostate and lung cancer cells by downregulating the expression of chemokine receptor CXCR4. Immunopharmacol Immunotoxicol. 2012;5:768–78.

    Google Scholar 

  106. Agell L, Hernandez S, Nonell L, Lorenzo M, Puigdecanet E, de Muga S, et al. A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression. Am J Pathol. 2012;5:1585–94.

    Google Scholar 

  107. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest. 2004;6:913–23.

    Google Scholar 

  108. Larkin SE, Holmes S, Cree IA, Walker T, Basketter V, Bickers B, et al. Identification of markers of prostate cancer progression using candidate gene expression. Br J Cancer. 2012;1:157–65.

    Google Scholar 

  109. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011;17:2391–6.

    Google Scholar 

  110. Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, et al. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol. 2012;11:1105–13.

    Google Scholar 

  111. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA. 2007;18:7564–9.

    Google Scholar 

  112. Stephenson AJ, Smith A, Kattan MW, Satagopan J, Reuter VE, Scardino PT, et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer. 2005;2:290–8.

    Google Scholar 

  113. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005;5:393–406.

    Google Scholar 

  114. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE. 2013;6:e66855.

    Google Scholar 

  115. Long Q, Xu J, Osunkoya AO, Sannigrahi S, Johnson BA, Zhou W, et al. Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence. Cancer Res. 2014;12:3228–37.

    Google Scholar 

  116. Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, et al. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol. 2015;4:555–67.

    Google Scholar 

  117. Oh JJ, Park S, Lee SE, Hong SK, Lee S, Lee HM, et al. A clinicogenetic model to predict lymph node invasion by use of genome-based biomarkers from exome arrays in prostate cancer patients. Korean J Urol. 2015;2:109–16.

    Google Scholar 

  118. Nordstrom T, Adolfsson J, Gronberg H, Eklund M. Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy. BMC Urol. 2017;1:92.

    Google Scholar 

  119. Leon-Mateos L, Casas H, Abalo A, Vieito M, Abreu M, Anido U, et al. Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients. Oncotarget 2017;33:54708–21.

    Google Scholar 

  120. Gorges TM, Kuske A, Rock K, Mauermann O, Muller V, Peine S, et al. Accession of tumor heterogeneity by multiplex transcriptome profiling of single circulating tumor cells. Clin Chem. 2016;11:1504–15.

    Google Scholar 

  121. Pal SK, He M, Chen L, Yang L, Pillai R, Twardowski P, et al. Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide. Urol Oncol. 2018;4:162.e1–162.e6.

    Google Scholar 

  122. Magadoux L, Isambert N, Plenchette S, Jeannin JF, Laurens V. Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review). Int J Oncol. 2014;3:919–28.

    Google Scholar 

  123. Chen M, Wang K, Zhang L, Li C, Yang Y. The discovery of putative urine markers for the specific detection of prostate tumor by integrative mining of public genomic profiles. PLoS ONE. 2011;12:e28552.

    Google Scholar 

  124. Li M, Zhou D, Zhang W, Gao S, Zhou X. Urine PCA3 mRNA level in diagnostic of prostate cancer. J Cancer Res Ther. 2018;4:864–6.

    Google Scholar 

  125. Bu H, Bormann S, Schafer G, Horninger W, Massoner P, Neeb A, et al. The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate. 2011;6:575–87.

    Google Scholar 

  126. O’Reilly E, Tuzova AV, Walsh AL, Russell NM, O’Brien O, Kelly S, et al. epiCaPture: A urine DNA methylation test for early detection of aggressive prostate cancer. JCO Precis Oncol. 2019;2019.

  127. Ciardiello C, Leone A, Lanuti P, Roca MS, Moccia T, Minciacchi VR, et al. Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation. J Exp Clin Cancer Res. 2019;1:317.

    Google Scholar 

  128. Minciacchi VR, You S, Spinelli C, Morley S, Zandian M, Aspuria PJ, et al. Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles. Oncotarget. 2015;13:11327–41.

    Google Scholar 

  129. Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ, et al. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 2009;13:5601–9.

    Google Scholar 

  130. Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, et al. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol. 2012;5:1573–84.

    Google Scholar 

  131. Minciacchi VR, Spinelli C, Reis-Sobreiro M, Cavallini L, You S, Zandian M, et al. MYC mediates large oncosome-induced fibroblast reprogramming in prostate cancer. Cancer Res. 2017;9:2306–17.

    Google Scholar 

  132. Fraser M, Berlin A, Bristow RG, van der Kwast T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol Oncol. 2015;2:85–94.

    Google Scholar 

  133. Lindberg J, Klevebring D, Liu W, Neiman M, Xu J, Wiklund P, et al. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol. 2013;2:347–53.

    Google Scholar 

  134. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell. 2015;4:1011–25.

    Google Scholar 

  135. Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015;7:736–45.

    Google Scholar 

  136. Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, et al. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013;24:1881–90.

    Google Scholar 

  137. Zhao L, Yu N, Guo T, Hou Y, Zeng Z, Yang X, et al. Tissue biomarkers for prognosis of prostate cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev. 2014;6:1047–54.

    Google Scholar 

  138. You S, Knudsen BS, Erho N, Alshalalfa M, Takhar M, Al-Deen Ashab H, et al. Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome. Cancer Res. 2016;17:4948–58.

    Google Scholar 

  139. Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol. 2013;5:920–6.

    Google Scholar 

  140. Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Epstein JI, et al. Current histopathologic and molecular characterisations of prostate cancer: towards individualised prognosis and therapies. Eur Urol. 2016;2:186–90.

    Google Scholar 

  141. Yang L, Wang S, Zhou M, Chen X, Jiang W, Zuo Y, et al. Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. Sci Rep. 2017;1:738.

    Google Scholar 

  142. Modena A, Iacovelli R, Scarpa A, Brunelli M, Ciccarese C, Fantinel E, et al. Investigating BRCA mutations: a breakthrough in precision medicine of castration-resistant prostate cancer. Target Oncol. 2016;5:569–77.

    Google Scholar 

  143. Kamoun A, Cancel-Tassin G, Fromont G, Elarouci N, Armenoult L, Ayadi M, et al. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Ann Oncol. 2018;8:1814–21.

    Google Scholar 

  144. Ketola K, Munuganti RSN, Davies A, Nip KM, Bishop JL, Zoubeidi A. Targeting prostate cancer subtype 1 by forkhead Box M1 pathway inhibition. Clin Cancer Res. 2017;22:6923–33.

    Google Scholar 

  145. Wu YM, Cieslik M, Lonigro RJ, Vats P, Reimers MA, Cao X, et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 2018;7:1770. e14.

    Google Scholar 

  146. Almassi N, Reichard C, Li J, Russell C, Perry J, Ryan CJ, et al. HSD3B1 and response to a nonsteroidal CYP17A1 inhibitor in castration-resistant prostate cancer. JAMA Oncol. 2018;4:554–7.

    PubMed  Google Scholar 

  147. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, et al. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014;24:6269–76.

    Google Scholar 

  148. Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, et al. Transcriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment naive primary prostate cancer. Clin Cancer Res. 2019;22:6721–30.

    Google Scholar 

  149. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;136:136ra68.

    Google Scholar 

  150. Lambros MB, Seed G, Sumanasuriya S, Gil V, Crespo M, Fontes M, et al. Single-cell analyses of prostate cancer liquid biopsies acquired by apheresis. Clin Cancer Res. 2018;22:5635–44.

    Google Scholar 

  151. Oliveira KCS, Ramos IB, Silva JMC, Barra WF, Riggins GJ, Palande V, et al. Current perspectives on circulating tumor dna, precision medicine, and personalized clinical management of cancer. Mol Cancer Res. 2020;4:517–28.

    Google Scholar 

  152. Ku SY, Gleave ME, Beltran H. Towards precision oncology in advanced prostate cancer. Nat Rev Urol. 2019;11:645–54.

    Google Scholar 

  153. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020:Jco2000046.

  154. Murphy AB, Carbunaru S, Nettey OS, Gornbein C, Macias V, Sharifi R, et al. A 17-gene panel genomic prostate score has similar predictive accuracy for adverse pathology at radical prostatectomy in African American and European American Men. Urology. 2020;142:166–73.

    PubMed  Google Scholar 

  155. Tan SH, Petrovics G, Srivastava S. Prostate cancer genomics: recent advances and the prevailing underrepresentation from racial and ethnic minorities. Int J Mol Sci. 2018;19:4.

    Google Scholar 

Download references

Funding

NIH/NCI R01 CA232574.

Author information

Authors and Affiliations

  1. Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA

    Yuanshuo Alice Wang, John Sfakianos, Ashutosh K. Tewari & Natasha Kyprianou

  2. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA

    John Sfakianos, Ashutosh K. Tewari, Carlos Cordon-cardo & Natasha Kyprianou

  3. Department of Pathology and Laboratory Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA

    Carlos Cordon-cardo & Natasha Kyprianou

  4. Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA

    Natasha Kyprianou

Authors
  1. Yuanshuo Alice Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Sfakianos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ashutosh K. Tewari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlos Cordon-cardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Natasha Kyprianou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Natasha Kyprianou.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Y.A., Sfakianos, J., Tewari, A.K. et al. Molecular tracing of prostate cancer lethality. Oncogene 39, 7225–7238 (2020). https://doi.org/10.1038/s41388-020-01496-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-020-01496-5

This article is cited by

Search

Advanced search

Quick links